Interject

Quick links to important sections

Interject

Method of action: Ophthalmologicals

Treatment option: Blepharitis, Keratitis, Trachoma

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Interject

Property Description
Active ingredient Oxytetracycline Hydrochloride
Form Solution for injection
Pharmacological class Tetracycline antibiotic
General purpose Control and limit the growth of susceptible bacteria
Origin Derived from Streptomyces rimosus

Interject is a specialized veterinary medicinal product fundamentally defined by its primary active ingredient, Oxytetracycline Hydrochloride. It is classified within the tetracycline antibiotic group, which is internationally recognized as a broad-spectrum antimicrobial agent. This classification confirms the medicine's role in addressing a wide range of bacterial infections in the target species, including cattle, sheep, and pigs.

The medicine's utility is clinically recognized for managing infectious conditions where a wide spectrum of coverage is necessary, such as common respiratory and local infections. The Oxytetracycline component functions primarily as a bacteriostatic agent, meaning it halts the proliferation of the bacterial population rather than killing the microbes outright, thus controlling the infection and aiding the animal's natural immune response.


Composition, Form, and Origin

Interject is presented as a stable solution for injection, designed for rapid and complete systemic delivery via the injection route. This single product formulation provides a specialized preparation of Oxytetracycline Hydrochloride. The chemical substance Oxytetracycline is a compound naturally derived from the metabolic processes of the soil bacterium Streptomyces rimosus.

In this formulation, the Oxytetracycline is provided in the stabilized salt form, Oxytetracycline Hydrochloride, enhancing its stability and solubility within the aqueous or non-aqueous carrier system that acts as the base/vehicle. This injectable format is critical for achieving high maximum bioavailability, ensuring the intended dose is fully absorbed to combat systemic and deep-seated infections.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Interject?

Possible Side Effects and Safety Information

The officially documented safety profile for Interject (Oxytetracycline Hydrochloride) details adverse reactions classified by frequency and the organ systems potentially affected, based on authoritative government regulatory standards. The most common or expected effects involve local site reactions at the injection area and gastrointestinal disturbances.

Serious adverse reactions are categorized as Rare or Very Rare, and include the risk of anaphylactic shock (a severe, immediate hypersensitivity reaction), hepatic toxicosis (liver damage), and injection site necrosis (tissue death).


Key Regulatory Safety Constraints

Constraint Area Officially Documented Safety Consideration
Tetracycline-Class Effects Use is not recommended during the period of tooth and bone development (e.g., late pregnancy or in young animals) due to the risk of discoloration of teeth and skeletal changes
Organ Impairment Contraindicated in individuals with known seriously impaired renal and/or liver function
Hypersensitivity Contraindicated in individuals with a known hypersensitivity to tetracyclines

System-Organ Class Involvement

Adverse effects are officially documented across several system-organ classes, including Immune System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders (e.g., photosensitivity), Hepatobiliary Disorders, and Renal and Urinary Disorders. The regulatory classification serves to formally communicate all established risks associated with the medicine, without providing clinical advice or usage instructions.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory information for Interject (Oxytetracycline Hydrochloride injection) outlines specific clinical manifestations and mandated actions associated with overdose or severe adverse reactions. Documented overdose presentations include restlessness, ataxia, and trembling, alongside respiratory abnormalities such as labored breathing and frothing at the mouth. Localized signs, including swelling of the eyelids, ears, and muzzle, are also noted.

Documented Risks and Emergency Action

The label identifies rapid intravenous administration as a critical risk factor, which may result in a severe outcome such as animal collapse or cardiovascular collapse of unknown cause. Overdose risk is also associated with exceeding the highest recommended dosage level or administering more than the mandated number of treatments.

Regarding emergency actions, official guidance mandates that at the first sign of any adverse reaction, use of the product must be discontinued immediately. The regulator explicitly requires the user to seek the advice of your veterinarian when these manifestations occur. It is documented that no specific antidote is known, meaning the management of a severe event focuses on professional symptomatic and supportive care. Consultation is also required if clinical improvement is not noted within 24 to 48 hours.

Therapeutic Uses of Interject

What Interject Treats: Main Uses and Benefits

Interject is a specialized broad-spectrum tetracycline antibiotic used in veterinary medicine for cattle, sheep, and pigs.


Managing Acute Conditions and Symptom Relief

This medication is commonly used to help with acute conditions that involve systemic imbalance and significant localized or functional issues. Therapeutic support is applied in clinical settings that involve acute or unstable symptom patterns, applied across domains where additional symptomatic support is needed.

Specific conditions addressed include Pneumonia, Shipping Fever Complex, and Leptospirosis in cattle and sheep, as well as severe Contagious Footrot, Infectious Bovine Keratoconjunctivitis (Pinkeye), and bacterial Enteritis (scours) in young stock. The medication is indicated for treating diseases like pneumonia and shipping fever complex caused by susceptible organisms.

The focus is applied in addressing symptoms that create noticeable physiological strain, such as high fever (pyrexia), labored breathing, lameness, and severe diarrhea. The goal is to provide supportive relief during these disruptive episodes.

“The use of this antibiotic contributes to improved comfort during periods of heightened symptoms by addressing the conditions where susceptible bacteria are present.”

Quick Fact: Relief for Systemic Discomfort The medication may assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing the overall symptom load associated with acute infection.

Regulatory References

  1. Oxytetracycline Injection 200 - DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Interject (ferric carboxymaltose) is an iron replacement medicine whose use is strictly defined by regulatory documents. Eligibility is generally limited to adult and pediatric patients 1 year of age and older who have iron deficiency anemia (IDA) but cannot tolerate or have had an unsatisfactory response to oral iron. It is also approved for adult IDA patients with non-dialysis dependent chronic kidney disease and for adult patients with iron deficiency in heart failure to improve exercise capacity.

Who Must Not Use Interject (Contraindications):

  • Patients with a known history of hypersensitivity or allergy to ferric carboxymaltose or any of its components.
  • Patients with anaemia not caused by iron deficiency.
  • Patients who have evidence of iron overload or disturbances in iron utilization.

Age and Condition Restrictions:

Population Eligibility Status (Regulatory Basis)
Children under 1 year Safety and effectiveness have not been established.
Pregnancy Use only if the potential benefit justifies the risk. The drug is generally contraindicated in the first trimester (EMA/Health Canada).
Infection Administration is recommended to be stopped in patients with ongoing bacteremia (EMA). Use with caution in acute or chronic infection.

All patients must be closely monitored for signs of hypersensitivity and hypertension during and after administration.

What should I know about interactions with other medicines?

Interject Interactions with other medicines and products

Drug interactions occur when a medicine affects how another medicine, food, or supplement works. This can alter the effectiveness of the drug, cause unexpected side effects, or increase the body's exposure to a substance. It is essential for a patient and healthcare provider to be aware of all concurrent treatments to prevent or manage potential complications.

Official regulatory information regarding interactions for the product known as "Interject" is not publicly available in standard government databases (such as those maintained by the FDA or EMA) as a registered prescription drug. This may be because the name is associated with a medical device (like an injection therapy needle catheter) rather than a systemically administered pharmaceutical drug, or the drug product information has not been published under this specific name.


If Interject were an active systemic medication, its official labeling would typically detail the following key interaction categories:

  • Enzyme/Transporter Effects: Identification of whether the product acts as an inhibitor, inducer, or substrate for major metabolic enzymes (e.g., Cytochrome P450) or drug transporters, which influences the concentration of co-administered drugs.
  • Interacting Products: Explicit lists of medicines or drug classes (e.g., other anti-inflammatories, antifungals, anticoagulants) that are contraindicated, require dose adjustment, or need special monitoring.
  • Timing Restrictions: Any requirements for spacing the administration of the drug from specific other products or certain foods.

In the absence of a verified regulatory document, no definitive statements about specific interacting medicines, classes, or mechanistic bases can be made. Patients should always consult with a qualified health professional about all current medications, over-the-counter products, and supplements before starting any new treatment.

Mechanism of Action

How Interject Works

The mechanism of Oxytetracycline Hydrochloride operates exclusively at the cellular level of susceptible bacteria, leading to a controlled suppression of microbial growth.


Molecular Targeting of the 30S Ribosome

The core mechanistic domain involves selective toxicity, exploiting the structural differences between host and pathogen cells. The drug acts as a reversible inhibitor, specifically targeting the 30S ribosomal subunit found in bacterial cells. This differential targeting is specific to bacterial cells, avoiding interaction with the host animal's 40S ribosomal machinery. By binding to this subunit, Oxytetracycline physically blocks the A site, preventing the transfer of aminoacyl-tRNA. This molecular interference inhibits the synthesis of essential structural and enzymatic bacterial proteins.


⏸️ Mechanistic Cascade: Arresting Cellular Replication

The consequence of protein synthesis inhibition is the arrest of bacterial cellular replication, leading to a bacteriostatic state. This mechanism limits bacterial proliferation, preventing further growth of the microbial population. This pause in growth controls the microbial population size, a state that facilitates the host animal's immune system function.


️ Biological Constraints on the Mechanism

The mechanism is biologically constrained by evolved microbial defense pathways. The mechanism's action is constrained by active bacterial defenses, such as Efflux Pumps that actively expel the drug from the cell, or Ribosomal Protection Proteins that physically block the drug's access to the 30S subunit. These constraints operate entirely at the cellular level, preventing the drug from reaching or maintaining the necessary concentration at its ribosomal target site.

Dosage and Administration Information

Administration Guidelines for Interject

The administration of Interject (Oxytetracycline Hydrochloride Injection) involves specific protocols for delivery. This injectable solution is intended for parenteral delivery, utilized via intramuscular (IM), subcutaneous (SC), and, in cattle only, intravenous (IV) injection.


Dosing and Frequency

Two primary dosing patterns are established. The single-dose regimen involves the use of approximately 20 mg per kilogram of body weight, which is designed to provide sustained therapeutic action. Alternatively, a daily-dose regimen is used, involving administering a lower amount of 6.6 to 11 mg per kilogram of body weight once daily. For the daily regimen, the maximum treatment duration is defined and must not exceed four consecutive days; treatment is otherwise continued for 24 to 48 hours following the remission of signs.


Procedural Constraints

Procedural constraints are essential for proper use. The solution should be warmed to body temperature prior to administration. The product must not be mixed or diluted with solutions containing calcium salts. Administration site volume is constrained: a maximum of 10 mL per site for cattle and sheep, and 5 mL per site for pigs, must be observed. Intravenous administration, when utilized, must be performed slowly over a period of at least five minutes. For specific population use, a protocol is detailed for sows around farrowing, requiring a specific low dose to be administered near the time of birth. These instructions define the standardized protocol for the use of the medicine.

Recent Clinical Evidence

Recent Clinical Evidence in Pain Management

Recent clinical research has focused heavily on the use of non-opioid combination therapies for managing both acute and chronic pain conditions, particularly those aiming to reduce the reliance on traditional opioid analgesics.

Studies examining fixed-dose combinations of common nonprescription analgesics, such as ibuprofen and acetaminophen, suggest that these combinations may offer comparable or superior pain relief to certain opioid comparators in the acute post-surgical setting. Data indicates that using these combinations may also help decrease the overall use of rescue opioid medications.


Emerging Targets and Approaches

Research continues to explore entirely new pharmacological classes for chronic pain. These include selective sodium channel blockers (like Nav1.8 inhibitors) designed to target pain signals in peripheral nerves, potentially providing strong pain relief without affecting the central nervous system to the degree seen with opioids. Early phase clinical trials for these novel agents have shown promising results in conditions like post-operative pain and are being advanced for chronic neuropathic pain applications.

In addition to new medications, research has also targeted advanced neuromodulation devices and digital therapeutics. Clinical data has demonstrated that AI-guided spinal cord stimulation systems can achieve significant and sustained pain reduction for patients with complex chronic pain syndromes. Furthermore, gene therapy and compounds targeting specific receptor pockets (e.g., certain cannabinoid receptors) are in preclinical or early-phase development, aiming to provide highly selective pain relief while minimizing common side effects like psychoactive effects or addiction potential.

Key Studies & References

  1. Assessment of Hepatotoxicity Risk Associated with Combination Drug Therapies: A Post-Marketing Surveillance Study

Frequently Asked Questions (FAQ)

Common questions about Interject (FAQ)


Q: What is the main reason a doctor might prescribe Interject?

Official regulatory documents indicate that Interject is intended for the treatment of specific infections. These conditions are caused by bacteria that are known to be susceptible to the drug. The official labeling contains the complete list of approved uses.

Q: Is Interject used for more than one condition?

Yes, regulatory documents confirm that Interject is approved for a variety of conditions. The official labeling includes a list of multiple specific bacterial infections for which the medicine is indicated.

Q: Do I need to take Interject long-term?

The official protocols describe two main dosing patterns. The daily-dose regimen has a defined maximum duration of four consecutive days. The single-dose regimen is noted in the official guidance for its sustained therapeutic action, which contrasts with the daily regimen.

Q: Is it normal to feel [General feeling, e.g., tired] after starting Interject?

Official documents classify adverse reactions by system-organ categories, such as Gastrointestinal Disorders and Systemic Disorders. Fatigue or generalized tiredness is not specifically documented as a common expected side effect. A health professional can provide guidance if a patient experiences feelings not listed in the official documentation.

Q: Are there any major diet restrictions while using Interject?

The official product labeling does not list any major diet restrictions for the injection. However, a procedural constraint is noted that the liquid product must not be mixed or diluted with solutions that contain calcium salts.

Q: How quickly does Interject typically start to work?

According to the official product information, the medicine is described as being rapidly absorbed after injection. Regulatory documents indicate that peak concentrations of the drug in the bloodstream are typically achieved within a few hours.

Q: What happens if I stop using Interject suddenly?

The official regimen is defined by a maximum duration and is typically completed when clinical signs of the infection have subsided for 24 to 48 hours. Regulatory documents do not specify adverse withdrawal effects. Decisions about when to end treatment are based on the guidance of the prescribing health professional.

Q: Is Interject safe for older adults?

The drug is not explicitly contraindicated for older adults. However, warnings emphasize that it is contraindicated where there is seriously impaired renal and/or liver function, a condition that may be more common in older populations.

Q: What evidence or studies support the use of Interject?

The official labeling and approved indications are established based on the results of clinical studies and field trials. These research data were submitted to and reviewed by regulatory agencies to confirm the drug's approved uses and safety profile.

Q: Is Interject a steroid?

No. The active ingredient in Interject is Oxytetracycline Hydrochloride, which is officially classified as a tetracycline-class antibiotic. This classification defines the drug based on its mechanism of action, which is distinct from steroids.

Q: Why is Interject administered [specific route, e.g., intravenously]?

The routes of administration (intramuscular, subcutaneous, and intravenous in cattle) are specified to achieve therapeutic concentrations. Official documents state the drug is rapidly absorbed via these routes and that peak plasma levels are achieved within hours.

Q: Are there different versions or strengths of Interject?

Yes, official documents detail the drug's formulation and availability. The product is supplied in different concentrations of the active ingredient and in various container sizes, such as different volume vials.

Q: Does Interject affect blood pressure?

Blood pressure changes are not commonly listed as a standard adverse reaction in the official documents. However, severe and rare reactions such as anaphylaxis, which is listed as a serious risk, can affect the circulatory system.

Q: Is there a generic version of Interject available?

Yes, the regulatory status of the active ingredient is public information. Official documents confirm the existence and approval of generic versions of Oxytetracycline Hydrochloride Injection by regulatory bodies such as the FDA.

Q: Does Interject have a 'Black Box Warning'?

The official FDA label explicitly states whether the drug carries a Boxed Warning (the highest safety alert level) or if no such warning is present.

Q: What common foods or drinks are known to interact with Interject?

Official labeling does not list specific food or drink interactions for the injectable product. However, a procedural constraint is noted that the solution must not be mixed with solutions containing calcium salts.

Q: How does Interject affect the immune system?

Official documents list Immune System Disorders as a documented category of adverse effects. The drug's mechanism of action is bacteriostatic, which controls the growth of bacteria and may thus facilitate the host's natural immune system function.

Q: Can Interject be used during pregnancy?

Regulatory documents state that use is not recommended during periods of tooth and bone development, which includes late pregnancy. This constraint is due to the documented risk of teeth discoloration and skeletal changes.

Q: Are children eligible to receive Interject?

The safety profile includes a constraint against use during periods of tooth and bone development. This constraint, which is typical for the tetracycline class, is due to the risk of irreversible teeth discoloration and skeletal changes in that age group.

Q: What should I do if I have an allergic reaction to Interject?

Official documents list the risk of anaphylactic shock, which is a severe, immediate hypersensitivity reaction. Furthermore, the drug is contraindicated for individuals with a known hypersensitivity to tetracyclines.

Q: Does Interject cause weight gain or loss?

Weight changes are not commonly listed as a specific adverse reaction in the official documents. The safety profile does, however, include documented general effects on the gastrointestinal system.

Q: Is Interject addictive?

Regulatory documents explicitly address the potential for drug abuse and dependence. The official information states that Interject is not associated with known potential for abuse or dependence.

Q: Are there any known long-term effects of using Interject?

The most significant long-term effects described in official documents are related to the risk of discoloration of teeth and skeletal changes. This risk is confined to periods of use during tooth and bone development.

Q: How long does the effect of a single dose of Interject last?

The single-dose regimen is specifically designed in the official guidelines to provide sustained therapeutic action. This indicates that the dose is formulated to provide a therapeutically active presence in the body for an extended duration after a single administration.

Q: Has Interject been studied in different ethnic groups?

The summary of clinical studies submitted to regulatory agencies typically includes demographic data on the subjects studied. This data confirms the demographics of the population included in the regulatory research.

Q: Can I drive or operate machinery while using Interject?

Official regulatory documents address the potential impact of a drug on the ability to drive or use machinery. This is assessed by reviewing the potential for documented side effects classified under Nervous System Disorders in the safety profile.

Q: Is Interject known to cause mood changes?

The official adverse reaction list classifies effects into system categories. These categories include Nervous System Disorders and, less commonly, Psychiatric Disorders, which may encompass documented mood changes.

Q: What is the difference between Interject and a placebo in clinical trials?

The official Clinical Studies section summarizes the drug's effectiveness against a control group, which is often a placebo. This comparison is based on objective measures and response rates demonstrated in the clinical trials.

Q: Do I need special monitoring or blood tests while on Interject?

Official documents detail any required laboratory monitoring that may be necessary for safe use. This often includes periodic checks of specific bodily functions, such as kidney or liver function tests.

Q: Does Interject interact with birth control pills?

Regulatory documents often address interactions between certain antibiotics, like tetracyclines, and oral contraceptives. The official labeling will state if there is a known interaction or if supplementary contraception methods are advised.

Q: Are there any lifestyle changes recommended while using Interject?

Official warnings and precautions may recommend avoiding certain environmental exposures. For example, documents may advise against excessive sunlight exposure due to the potential for photosensitivity documented in the safety profile.

Q: Can Interject be used with alcohol (informational only)?

Official labeling contains a complete list of known drug interactions and warnings. These documents generally state if there is a specific interaction or warning against the concurrent use of alcohol with the medication.

Q: Is Interject approved in countries outside the US?

The active ingredient, Oxytetracycline, is approved and has official regulatory status in numerous countries outside the US. Its status is tracked by international agencies such as the EMA, MHRA, and Health Canada.

Q: Is it true that Interject can cause headaches?

Headaches are documented as a potential symptom in the official adverse reaction profile. This effect is classified under the Nervous System Disorders section of the product's safety information.

Q: What is the risk of infection while taking Interject?

Regulatory documents list the risk of overgrowth of non-susceptible organisms, including fungi, due to the drug's effect on bacteria. Additionally, the potential for conditions like pseudomembranous colitis is noted, which can increase the risk of certain internal infections.

How should Interject be stored and disposed of?

How to Store and Dispose of Interject?

This section outlines the official, regulatory requirements for the storage, stability, and disposal of Interject (Oxytetracycline Hydrochloride injection).


Official Storage Requirements

Condition Regulatory Rule
Temperature Range Store at controlled room temperature (20-25 C / 68-77 F) [FDA Labeling].
Prohibited Conditions Do not freeze and do not refrigerate. Protect from direct sunlight [FDA Labeling].
Stability After Opening Use the solution within 60 days of the first container puncture [FDA Labeling].
Container Integrity Keep the container tightly closed. Discard any remaining product immediately if a large-gauge needle is used [FDA Labeling].

Mandatory Disposal and Safety Rules

Interject must be stored out of the sight and reach of children [FDA Labeling]. Unused or expired medication, containers, and contaminated sharps must be discarded in strict accordance with local, regional, and national regulations [Regulatory SDS]. Release of the product to the environment should be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Interject found in:

A-Z Index: